

[www.deltacure2026.com](http://www.deltacure2026.com)

Chairs:  
**Pietro Lampertico  
and Heiner Wedemeyer**

# Delta*cure*

**5<sup>th</sup> International Meeting**



# ACCEPTED ABSTRACTS

**OCTOBER 15-16 2026 MILAN, ITALY**

## ORAL PRESENTATIONS

### EPIDEMIOLOGY, VIROLOGY AND IMMUNOLOGY

#### Global and Local Epidemiology

- 17 High prevalence of HDV and HBV detected amongst household contacts of HDV positive individuals in rural Sindh SS. Hamid

#### Virology: the latest insights

- 81 Paired liver and serum deep sequencing reveals differences between circulating HDV and intrahepatic viral populations J. Ringlander

#### Immunology update and spatial transcriptomics

- 37 Identification of GBP3 as a Novel Host Factor Required for Hepatitis Delta Virus Recognition by Hepatocytes R. Fouillé

### DIAGNOSIS AND NATURAL HISTORY

#### Diagnostics update

- 83 Quantitative anti-HDV measurement as a diagnostic surrogate of HDV replication E. Dileo

#### Natural history

- 69 Predictors of advanced chronic liver disease (ACLD) in patients with hepatitis delta virus (HDV) infection: does the genotype matter?  
M. Cardoso

### CURRENT AND NEW ANTIVIRAL TREATMENTS

#### Long-term outcomes in BLV-treated patients

- 56 Clinical and economic value of early treatment with bulevirtide in chronic hepatitis delta virus R. Dominguez
- 3 Hepatic recompensation according to Baveno VII in decompensated chronic hepatitis Delta treated with bulevirtide: a multicenter experience  
M. Meszaros

#### Other therapeutic approaches for HDV

- 95 Predicting time to cure in HDV patients treated with bulevirtide and pegylated interferon-alpha in the SEE-D trial  
H. Dahari
- 104 Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial  
N. Reau
- 118 The efficacy and safety of siRNA ozisiran in patients with chronic hepatitis D: Interim results through treatment Week 36 from the phase 2a RC04T001 trial K. Lindahl

## POSTER EXHIBITION

### EPIDEMIOLOGY, VIROLOGY AND IMMUNOLOGY

#### Global and Local Epidemiology

- 2 **Hepatitis D remains overrepresented and undertreated in prison populations: data from Catalonia, Spain**  
A. Marco, A. Palom, I. Abdo, A. Rando-Segura, L. Calatayud, G. Fernández-Rivas, A. Sellés, S. Mormeneo, D. Pérez del Campo, E. del Corral, ED. Gil-Tubella, M. Buti
- 13 **Integration of reflex hepatitis D virus screening into the national viral hepatitis elimination programme in Uzbekistan**  
M. Khodjaeva, E. Musabaev, I. Egamova, V. Rakhimova, E. Joldasova
- 14 **Single-Center Experience on Rates of Hepatitis D Testing and Electronic Medical Record Coding in Patients with Known Hepatitis B Infection**  
E. Hall, D. Rosario, N. Reau
- 17 **High prevalence of HDV and HBV detected amongst household contacts of HDV positive individuals in rural Sindh**  
A. Ali, H. Ahmed, SM. Channa, C. Strobel, M. Rodgers, S. Gawel, F. Averhoff, G. Cloherty, E. Khan, N. Ghanchi, SS. Hamid
- 31 **Real-world adherence to HDV reflex testing among HBsAg-positive patients in Pakistan: Are we missing HDV?**  
F. Nadeem, S. Memon, U. Ghani, A. M. Burney, H. Soomro, S. Ali
- 35 **Global burden and geographic concentration of hepatitis delta virus infection across 195 countries in 2020: A modeling study**  
M. Papatheodorid, J. Paik, K. AlNaamani, G. Papatheodoridis, M. Buti, A. Paik, T. Kushner, C. Villela-Nogueira, S. Gidaagaya, B. Munkhbat, M. Yu, J. Ong, Y. Eguchi, M. El-Kassas, P. Lampertico, Y. Yilmaz, C. Spearman, Z. Younossi
- 36 **Clinical phenotype of hepatitis D according to HIV serostatus: results from the nationwide DDR Spain cohort**  
A. Alberola, A. de Salazar, A. Fuentes, R. Carracedo, M. Illescas-López, L. Pérez-Rodríguez, A. Vázquez-Blanquino, M. Cabezas Fernández, C. Freyre, B. Becerril, I. Viciano, I. López-Rodríguez, N. Montiel Quezel-Guerraz, S. Bernal, J. Borrego, E. Ramírez Arellano, C. Liébana-Martos, F. Franco Álvarez de Luna, M. Lozano, I. de Toro, A. Sampedro, A. Pérez, S. Algarate, P. Fraile, D. Ocete, I. Corrales, O. Martínez, V. Domínguez, N. Orta, S. Sabater Vidal, L. Navarro, E. Aguirre, J. Magraner Egea, A. Vallejo, M. Aroca, T. Tosco Núñez, M. Lara, M. Pena, A. Rodríguez-Fernández, A. González Praetorius, E. Simarro Córdoba, A. Beteta, C. Gómez, M. Rodríguez Escudero, J. García Díez, M. Sandoval Torrientes, R. Sáez, P. Tajada Alegre, B. Lorenzo, M. García Valero, S. García-de Cruz, S. Garcinuño, S. Muñoz, H. Lorenzo Juanes, M. Vidal-Acuña, L. Moldes, N. Calvo, M. Gude, P. Ordóñez, S. Cortizo, M. Blasco, I. Falces, J. Galán, A. Arribi, R. Alonso, A. Iborra, M. del Amor Espín, E. Cascales, M. Nuñez, J. Galán Ros, A. Miqueleiz, L. Elorduy, M. Macho, C. Gómez, P. Liendo, M. Montes Ros, A. Aguilera, F. García
- 39 **Where should we look for hepatitis D? Community versus hospital-based screening in Romanian migrants in Catalonia, Spain.**  
A. Palom, J. Gómez i Prat, T. Rafi, S. Malik, L. Buldum, I. Abdó, A. Marco, P. Huelin, C. Aracil Blanch, C. Lopez, T. Balari, J. Castellote, R. Maria Morillas, M. Buti
- 65 **National registry of patients with hepatitis D: real-world clinical practice data in Spain**  
A. Pocurull, A. Palom, Á. Giraldez, JC Ruiz Cobo, M. Casado, S. Lorente, J. García-Samaniego, M. Molina, R. González Monasterio, I. Fernández, C. Delgado, J. Cabezas, MJ. Devesa, JM. Rosales, N. García Gimeno, M. García-Retortillo, MD. Antón Conejero, R. Ríos, V. Escrich Iturbe, M. Rodríguez, M. Fernández Bermejo, M. Hernández-Conde, P. Rendón Unceta, M. Riveiro Barciela, X. Forn, M. Buti, S. Lens
- 74 **Epidemiology and clinical characteristics of hepatitis delta virus infection in Belgium: Final results of a nationwide double HDV reflex testing study**  
M. Coessens, F. Lemaître, I. Roukaerts, J. Wawrzyniak, M. Steverlynck, M. Van Esbroeck, BJ. Visser, M. Reda, M. De Vos, M. Reynders, H. Orlent, H. Vanpoucke, C. De Vloo, A. De Spiegeleer, J. Van Acker, L. Coremans, T. Banica, E. Padalko, X. Verhelst, H. Besse-Hammer, L. Lasser, A. Scohy, G. Zorzi, Y. Horsmans, N. Yin, C. Moreno, S. Goes, A. Van Dalem, S. François, P. Beckers, MP. Hayette, J. Delwaide, S. Vandamme, H. Dahma, S. Van den Wijngaert, T. Sersté, K. Hoet, M. Van Herck, P. Bruynseels, N. Van Gasse, S. Bourgeois, W. Verlinden, M. Mukovnikova, A. Vodolazkaia, S. Van Gucht, T. Vanwolleghem
- 84 **The Economic Burden of Chronic Hepatitis Delta Treatment in Mongolia**  
G. Jargalsaikhan, B. Dashtseren, B. Narantuya, T. Ulziibadrakh, O. Lkhagva-Ochir, N. Dashdorj
- 85 **Seroprevalence and viral biomarker characterization of hepatitis D infection in treatment naive-infected blood donors with hepatitis B in Cameroon**  
R. Kamga Wouambo, N. Ashukem Taku, N. S. Ateba, M. Pfefferkorn, S. Nkongolo, GE. Gnouamozi, M. Matz-Soja, S. Urban, T. Berg, F. van Bömmel, F. Ngo Nsack
- 89 **Reflex testing reveals a significant HDV burden across Europe and increases HDV diagnosis at an early stage**  
I. Grossi, R. Salpini, C. Tramontozzi, I. Alexiev, L. Baiocchi, L. Banica, T. Banica, J. Begovac, B. Benkoova, A. Bertoli, S. Bopegamage, C. Caudai, S. D'anna, T. Demir, C. Devaux, A. Di Lorenzo, G. Fernández-Rivas, K. Gazdikova, A. M. Geretti, E. Golkocheva-Markova, S. Grelli, E. Heger, G. Iserentant, L. Jancoriene, L. Svetikas, R. Kaiser, N. Kokkinos, I. Lazarevic, I. Milosevic, V. Lazureanu, K. Leuzinger, M. Lindh, J. Llibre, M. Lunar, U. Mickute, J. Mihale, I. Milosevic, O. Mor, D. Nierhoff, D. Otelea, P. Paba, E. Padalko, L. Piermatteo, M. Poljak, A. Riccio, M. Ruzic, L. Sarmati, G. Torre, A. M. Tudor, A. Vata, K. Tulay Yalçinkaya, D. Yildiran, M. Zazzi, A. Wensing, V. Svicher
- 100 **Searching for HDV to Find HBV infection; Impact of HDV Screening in Detecting New HBV Infections**  
I. Zagni, R. Stupia, F. Paolo Bonfante
- 101 **Hepatitis delta screening and treatment cascade among people with HIV and chronic hepatitis B in Milan**  
T. Clemente, A.R. Raccagni, R. Lolatto, H. Hasson, E. Messina, M. Ripa, V. Spagnuolo, A. Danise, M. Guffanti, P. Cinque, D. Canetti, S. Nozza, A. Castagna
- 52 **Opportunistic hepatitis screening reveals a hidden burden of hepatitis d and advanced liver fibrosis among hbsag-positive patients presenting with gastrointestinal symptoms in Pakistan**  
F. Nadeem, U. Ghani, S. Memon, B. Kadir, R. Bhatti, AH. Soomro

## POSTER EXHIBITION

### Virology: the latest insights

- 10 **Precision-cut liver slices as a model for evaluating therapeutic agents against HBV and HDV**  
M. Michelet, A. Roca Suarez, M. Plissonnier, A. Dubois, A. Diederichs, S. Heintz, M. Saez-Palma, M. Ben Abu, X. Grand, A. Favre, A. Chédotal, N. Van Renne, S. Fletcher, F. Mithieux, P. Bonnot, A. Dupré, N. Mouton, M. Rivoire, S. Phillips, E. Palma, S. Chokshi, F. Zoulim, B. Testoni
- 11 **Interferon Response and Cell Division–Mediated Spread of Patient-Derived Hepatitis D Virus Strains**  
G.E. Gnouamozi, J. Ringlander, J.B. Stenbäck, L. Mellert, F. Donati, S. Nkongolo, S. Urban
- 12 **A novel in vitro hepatocyte model of chronic propagative Hepatitis Delta Virus infection for long-term antiviral evaluation and host factor discovery**  
F. Bernardin, F. Pastor, C. Pons, R. Fouillé, O. Diaz, F. Habersetzer, T.F. Baumert, E.R. Verrier, D. Durantel and J. Lucifora
- 15 **What is the relationship between HBV DNA, HDV RNA and liver fibrosis among persons with HBV/HDV co-infection in Ethiopia?**  
T. Simbo, W. Abegaz, F. Schlund, F. Le Gal, A. Gerber, S. Zheng, A. Negash, F. Gudisa, D. Birhanu, A. Hussien, W. Cheneke, E. Gudina, S. Nkongolo, F. Lempp, N. Berhe, H. Mekonnen, L. Rossvoll, S. Urban, A. Johannessen
- 18 **A new humanized mouse model demonstrates HBV DNA integration-driven HDV spread mimicking chronic hepatitis D**  
C. Hingst, M. Schäfer, T. Volz, A. Volmari, K. Riecken, L. Bitar, M. Lütgehetmann, M. Zimmermann, B. Fehse, M. Dandri, L. Allweiss
- 21 **Kinetics of HBcrAg during Bulevirtide monotherapy in patients with HDV-related cirrhosis: a single-center real-world study**  
E. Degasper, F. Facchetti, D. Sambarino, C. Scholtes, B. Testoni, S. Uceda Renteria, M.P. Anolli, C. Charre, M.L. Plissonnier, R. Perbellini, A. Callegaro, M. Leviero, F. Zoulim, P. Lampertico
- 29 **Host immunogenetics and first sequencing-based characterization of HDV in Uzbekistan**  
E. Kazakova, E. Musabaev, Z. Ismailova, M. Khodjaeva
- 30 **Association of IL28B gene polymorphisms rs8099917 and rs12979860 with progression of chronic hepatitis D**  
D. Abdurakhimova, N. Ibadullaeva, A. Khikmatullaeva, N. Kan
- 45 **One protein, many roles: Large HDAG controls viral assembly, replication and cytopathic effects to sustain viral persistence**  
B. Zehnder, J. Bauer, Y. Ni, Z. Zhang, A. Beer, A. Prawira, S. Urban
- 61 **Treatment of hbv-hdv hepatitis in a solid organ transplant recipient patient: a case report**  
E. Gabrielli, C. Valeriani
- 51 **Cell proliferation reduces innate antiviral defenses and promotes HDV spread in primary human hepatocytes in vivo**  
A. Volmari, T. Volz, J. Chen, L. Allweiss, M. Lütgehetmann, S. Fletcher, M. Holdorf, M. Dandri
- 57 **Pre-treatment and on-treatment markers of HBV cccDNA transcription predict virological response in chronic hepatitis D treated patients with pegylated-interferon or Bulevirtide**  
I. Carey, Z. Cargill, M. Anderson, J. Lok, T. Fortney, G. Cloherty, G. Dusheiko, K. Agarwal
- 59 **Comparative Laboratory Evaluation of the RoboGene HDV RNA Quantification Kit 2.0 for Quantitative Detection of Hepatitis D Virus RNA**  
L.Z. Alieva, E.A. Joldasova, N.G. Kan, D.T. Suyarkulova, R.H. Juraev, E.I. Musabaev
- 71 **Hepatitis-B core-related antigen (HBcrAg), phosphorylated HBcrAg, and HBsAg isoforms as biomarkers of viral activity in chronic HDV infection: Do they mirror HDV RNA status?**  
I. Carey, Z. Cargill, M. Anderson, R. Geissler, T. Fortney, J. Lok, G. Cloherty, G. Dusheiko, K. Agarwal
- 76 **Clinical and virological characteristics of patients with low HDV RNA: HBV transcriptional activity persists despite minimal replication**  
I. Carey, Z. Cargill, M. Anderson, J. Lok, T. Fortney, R. Geissler, G. Cloherty, G. Dusheiko, K. Agarwal
- 81 **Paired liver and serum deep sequencing reveals differences between circulating HDV and intrahepatic viral populations**  
J. Ringlander, J.B. Stenbäck, M. Andersson, G. Rydell, M. Lindh, M. Kann
- 91 **Discordance between two peripheral biomarkers of cccDNA transcriptional activity, namely HBV core related antigen and HBV RNA, in HBV-HDV co-infection.**  
J. Lok, M. Anderson, T. Fortney, Z. Cargill, G. Cloherty, J. McKeating, G. Dusheiko, K. Agarwal, I. Carey
- 99 **Health care resource utilisation and costs by disease state in adults with hepatitis delta virus in the United States**  
R. Wong, R. Gish, S. Dhuliawala, G. Leung, J. Lim, M. Rock, C. Kim
- 77 **Phylogeography and epidemiological history of hepatitis delta virus genotype 3 in South America**  
L. Honorato, M. Gouvea, W. Braga, A. da Costa, M. Rodgers, M. Berg, C. Silveira, E. Kallas, M. Thomazella, A. de Paula, M. Castilho, Y. Rodrigues, H. Paião, M. de Freitas, L. Ribeiro, D. Dall'Acqua, J. Queiroz, J. Salcedo, T. Dantas, R. Barboza, T. Tozetto-Mendoza, F. Averhoff, S. Witkin, G. Cloherty, C. Mendes-Correa
- 78 **Phylogeographic reconstruction reveals recent African–Atlantic dispersal of hepatitis delta virus genotype 8**  
L. Honorato, K. Fassihi, S. Witkin, C. Mendes-Correa

## POSTER EXHIBITION

### Immunology update and spatial transcriptomics

- 37 **Identification of GBP3 as a Novel Host Factor Required for Hepatitis Delta Virus Recognition by Hepatocytes**  
R. Fouillé, C. Pons, R. Barnault, E. Verrier, D. Durantel and J. Lucifora

---

- 38 **Bulevirtide treatment reduces activation of T cells in chronic HDV infection**  
S. Chowdhury, R. Hoblos, H. Begali, M. Anim, C. Jacobsen, M. Lissek, E.A. Oyinloye, A. Carpentier, CS. Falk, ARM. Kraft, M. Cornberg, H. Wedemeyer, L. Sandmann, H. Kefalakes

---

- 66 **Identification of peripheral immune cell populations in HDV untreated and Bulevirtide-treated patients**  
J. Pérez-Garreta, A. Palom, A. Carvalho-Gomes, I. Llaosa Ferrera, D. Tabernero, A. Rando Segura, J. Romero, M. Berenguer, J.C. Ruiz Cobo, M. Riveiro-Barcila, M. Buti, M.F. Cortese

---

- 117 **Bulevirtide increases taurocholic acid in hepatitis D patients leading to reduced NK cell proliferation capacity**  
P. Chen, C. Dietz-Fricke, T. More, K. Hiller, K. Deterding, N. Woller, H. Wedemeyer

---

- 62 **An immunocompetent Syrian hamster model of persistent HDV mono-infection validated for antiviral testing**  
E. Broeckhoven, Y. Vanhees, F. Van Bavel, R. Gijssbers, C. Van den Haute, Y.A. Alpizar, K. Dallmeier

---

- 63 **A high-content imaging-compatible innate immune response-based reporter system for HDV antiviral screening**  
Y. Vanhees, E. Broeckhoven, V. Neven, Y.A. Alpizar, K. Dallmeier

---

### Baveno VIII update

- 44 **Baveno criteria in HDV-related cirrhosis: toward a disease-specific model to safely avoid screening endoscopy (Baveno-HDV)**  
M.P. Anolli, E. Degasper, G. Tosetti, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, T. Reiberger, C. Schramm, MR. Brunetto, F. van Bömmel, S. Zaltron, L. Turco, C. Zöllner, TA. Santantonio, I. Carey, A. Federico, L. Sarmati, M. Buti, M. Cardoso, F. Morisco, M. Papatheodoridis, FP. Russo, A. Mangia, P. Toniutto, N. Coppola, Q. Wu, J. Dumortier, EG. Giannini, E. Rosselli Del Turco, S. Aleman, S. De Nicola, M. Maracci, L. Marinaro, M. Milella, A. Pellicelli, B. Pinchera, M. Puoti, D. Roulot, LS. Crocè, I. Maida, U. Merle, A. Pan, O. Torre, F. Pileri, A. Romano, M. Tonnini, P. Vitiello, R. Zampino, F. Cerini, P. Lampertico on behalf of the SAVE-D and D-SHIELD investigators

---

## DIAGNOSIS AND NATURAL HISTORY

### Diagnostics update

- 7 **Pan-genotypic detection and whole-genome sequencing of hepatitis D virus using the Illumina Viral Surveillance Panel v2**  
F. Le Gal, S. Dziri, V. Delagarde, A. Gerber, D. Roulot, S. Brichler

---

- 32 **Global practice patterns in hepatitis D virus screening and management: Results from an international survey of healthcare providers**  
M. Papatheodoridis, M. Buti, G. Papatheodoridis, P. Charatchoenwithaya, A. Bhadoria, J. Fan, B. Pearlman, C. Villela-Nogueira, S. Singh, S. Kakizaki, W. Chan, A. Kulkarni, A. Singal, A. Ostojić, J. Crespo, C. Tzeuton, J. Lai, L. Kondili, M. Batmunkh, M. Ayurzana, M. Yu, G. Goh, D. Karagiannakis, E. Lytyak, A. Goel, K. AlNaamani, C. Spearman, I. Jacobson, T. Kushner, D. Duger, Y. Eguchi, M. El-Kassas, S. Gidaagaya, S. Gordon, S. Khaderi, P. Lampertico, M. Lee, B. Namdag, P. Ocamo, M. Pessoa, N. Pyrsopoulos, F. Russo, Y. Yilmaz, L. Henry, F. Nader, A. Racila, M. Stepanova, J. Ong, Z. Younossi

---

- 40 **Evaluation of dried blood spots for automated hepatitis D nucleic acid testing**  
S. Retzlaff, P. Rosenstock, AJ. Castillo, K. Rottengatter

---

- 47 **Longitudinal HDV RNA monitoring reveals virological rebound despite sustained HIV and HBV suppression in a cirrhotic patient**  
E. Altavilla, L. Bortolani, C. Carafa, S. Figliomeni, A. Mauro, F. Alessi, G. d'Ettorre

---

- 54 **Development of a local panel for quality control of hepatitis delta virus PCR diagnostic kits**  
SA. Tursunova, RK. Jurayev, NG. Kan, DT. Suyarkulova

---

- 55 **Vibration-controlled transient elastography shows a high diagnostic value in the exclusion of cirrhosis and the detection of significant fibrosis in patients with chronic hepatitis D virus infection**  
A. Hahn, D. Roulot, E. Degasper, R. Layese, H. Wedemeyer, S. Aleman, P. Lampertico, K. Deterding, H. Kefalakes, L. Sandmann

---

- 60 **Implementation of reflex testing for hepatitis Delta into Uzbekistan's National Strategy and Action Plan for the Elimination of Parenteral Viral Hepatitis (2026–2030): validation of diagnostic screening tools**  
L. Alieva, E. Joldasova, N. Kan, R. Juraev, E. Musabaev

---

- 64 **Performance evaluation of the Cobas HDV assay for automated HDV RNA detection and quantification: implications for clinical diagnostics and treatment monitoring in patients with HDV infection**  
A. Kessler, S. Suresh Kumar, S. Giraldez Martinez, S. Zenebe Gebreab, M. Lin, J. Young, A. Hiergeist, B. Seiverth, C. Voitenleitner, P. Lampertico, M. Luetgehetmann

---

- 68 **Positive impact of anti-HDV reflex testing in all HBsAg+ patients**  
C. Valente, A. Carmo, R. Carvalho, J. Vaz, C. Lopes, T. Reis, P. Silva, G. Marques, L. Araújo

---

## POSTER EXHIBITION

- 70 **Inadequate HDV screening among patients with HBV in pregnancy and association of HDV with adverse pregnancy outcomes: results from a multi-center retrospective study**  
C. McNatt, H. Mallick, T. Kushner
- 83 **Quantitative anti-HDV measurement as a diagnostic surrogate of HDV replication**  
G.P. Caviglia, E. Dileo, G. Gioiello, A. Olivero, G. Mengozzi, A. Ciancio, G. Ricco, B. Coco, L. Marinaro, G. Cariti, C. Taibi, G. D'Offizi, R. Cotugno, G.A. Niro, A. Loglio, M. Viganò, C. Magni, D. Angrisani, V. Messina, V. Cossiga, M. Milella, G. Verucchi, E. Pontali, M. Pirisi, C. Coppola, A. Izzì, V. Di Marco, T. Santantonio, A. Marrone, N. Coppola, M. Rizzi, A.M. Cattelan, P. Toniutto, FR. Ponziani, R. Viganò, A. Federico, G. Bertino, M. Puoti, A. Civolani, M. Distefano, MR. Brunetto, M. Rizzetto, on behalf of the HDV DESCRIBE Study Group.
- 87 **Longitudinal comparison of RoboGene HDV RNA Quantification Kit 2.0 and 3.0 and an in-house HDV RNA assay during BLV and PEG-INF treatment**  
M. Pfefferkorn, J. Selmann, M. Matz-Soja, Beatrix Gey, C. Früchtel, A. Reinhardt, F. van Bömmel
- 92 **Diagnostic and care pathway delays among chronic hepatitis D patients in Pakistan: a mixed-methods study**  
U. Arzoo, Z. Abbas
- 115 **Clinical performances of the Roche Cobas HDV RNA quantification assay in untreated and Bulevirtide-treated CHD patients: a 4-assay comparative study**  
M.P. Anolli, S. Uceda Renteria, E. Degasper, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico

## Natural history

- 48 **Landmark Machine Learning Analysis to Identify One-Year Risk of Advanced Liver Disease in Individuals with Hepatitis Delta Virus Infection**  
L. Telep, L. Hong, B. Zhao, A. Singer, R. Wong
- 67 **Long-term natural history and prognostic factors in patients with chronic hepatitis delta: a single-center retrospective longitudinal study**  
S. Laviola, I. La Scuola, P. Ferrari, F. Federici, S. Parisse, A. De Santis, F. Ferri
- 88 **A pediatric case of chronic hepatitis B/D receiving multiple courses of antiviral therapy**  
F. Donati, N. Dashdor, G. Jargalsaikhan, Z. Doljoo, P. Michl, S. Urban, S. Nkongo
- 69 **Predictors of advanced chronic liver disease (ACLD) in patients with hepatitis delta virus (HDV) infection: does the genotype matter?**  
M. Ferreira Cardoso\*, E. Pádua\*, H. Coelho, D. Toscano, J. Branco, F. Peruzzo, G. Cristóvão, D. Abrantes, F. Pinto Ferreira, N. Faria, P. Pacheco, M. Manata, M. Canhoto, C. Silva, A. Reis, A. Vieira, A. Vaz, H. Cardoso, R. Pinho, L. Santos, R. Carvalho, I. Costa Santos, F. Capinha, I. Medeiros, C. Batouxas, P. Mesquita, F. Borges Santos, R. Bragança, C. Valente, A. Martins, F. Calinas, H. Cortes Martins, P. Nogueira, M. Verdelho Machado  
\*Both authors contributed equally to this work.
- 103 **Discordance between liver stiffness measurement and FIB-4 and its impact on the long-term risk of liver-related events in chronic hepatitis D**  
H. Kamal, G. Jargalsaikhan, S. Enkhtaivan, K. Lindahl, B. Dashtseren, O. Lkhagva-Ochir, T. Ulziibadrakh, A. Bungert, N.B. Dashdorj and S. Aleman

## HCC in HDV: pathogenesis, incidence and predictors

- 8 **Hepatocellular Carcinoma in Chronic Hepatitis D: A Nationwide Benchmark Pre-Bulevirtide era from the Italian PITER Cohort**  
G. Brancaccio, MG. Quaranta, ME. Tosti, B. Coco, MR. Brunetto, GB. Gaeta, LA. Kondili on behalf of PITER Collaborating Investigators
- 42 **HCC risk stratification during long-term Bulevirtide therapy: performance of PAGE-B and AMAP in compensated HDV cirrhosis**  
M.P. Anolli, E. Degasper, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D'Offizi, F. di Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridis, G. Papatheodoridis, F. van Bömmel, S. Lens, MR. Brunetto, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciancio, A. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, S. Metivier, C. Coffin, S. Poulin, A. Mangia, MN. Hilleret, U. Merle, M. Cardoso, A. Martins, C. Gouveia, K. Doucette, S. Borgia, M. Viganò, TA. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, I. Costa Santos, AM. Vieira, F. Pileri50, M Maracci51, M Tonnini52, JP Arpurt53, K Barange54, E Billaud55, S Pol56, A Gervais57, A Minello58, M Puoti59, A Horta60, M Machado61, D Fernandes, J. Oliveira, J. Vaz Alves, P. Lampertico
- 46 **Management of hepatocellular carcinoma in patients with chronic HBV-HDV infection undergoing Bulevirtide therapy**  
L. Iliescu
- 53 **Hepatitis D in Hepatitis B-associated hepatocellular carcinoma: a real-world Pakistani cohort reveals a high burden and advanced presentation**  
U. Ghani, F. Nadeem, S. Memon, B. Kadir, R. Bhatti

## POSTER EXHIBITION

### CURRENT AND NEW ANTIVIRAL TREATMENTS

#### BLV in clinical trials

- 90 **Immunological predictive factors for treatment response during bulevirtide therapy in HBV-HDV coinfectd patients.**  
C. Taibj, E. Cimini, G. Grassi, A. Caioli, A. Rianda, F. Cristofanelli, S. Pauciullo, V. Zulian, A.R. Garbuglia, A.M. Geretti, E. Biliotti, G. D'Offizi
- 112 **Discontinuation of bulevirtide monotherapy in patients with chronic hepatitis D: A prospective multicenter study (D-SOLVE BUL-STOP)**  
H. Wedemeyer, J. Kahlhöfer, E. Degasper, K. Sprinzl, C. Zöllner, S. Nkongolo, D. Sambarino, K. Port, J. Schulze zur Wiesch, B. Bremer, K. Steppich, A. Kraft, H. Kefalakes, A. Großhennig, R. Ringlsetter, L. Sandmann, P. Lampertico, K. Deterding, for the D-SOLVE Consortium
- 109 **Integrated efficacy analysis by HDV and HBV genotypes in patients with chronic hepatitis delta receiving bulevirtide**  
T. Stepanova, S. Aleman, T. Asselah, P. Bogomolov, M. Brunetto, V. Chulanov, G.S. Gherlan, P. Lampertico, V. Morozov, O. Sagalova, A. Streinu-Cercel, F. Zoulim, A. Lichtman, M. Li, H. Mo, D. Manuilov, H. Wedemeyer
- 114 **Long-term treatment with bulevirtide 2 mg improves Fatigue Severity Scale scores in patients with chronic hepatitis delta virus: Results from an exploratory analysis of the Phase 3 MYR301 trial**  
M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R.G. Gish, S. Zeuzem, J. Schulze zur Wiesch, M. Cornberg, M.R. Brunetto, D. Manuilov, A. Lichtman, M. Rock, C. Kim, S. Pandey, B. Singh, P. Lampertico
- 116 **No impact of antidrug antibodies on the efficacy of bulevirtide in chronic hepatitis delta: Insights from a 96-week integrated analysis**  
P. Lampertico, S. Aleman, H. Wedemeyer, A. Streinu-Cercel, P. Bogomolov, V. Morozov, T. Stepanova, S. Lazar, M. Brunetto, V. Chulanov, G.S. Gherlan, O. Sagalova, R.C. Mercier, L. Caro, M. Li, A. Lichtman, D. Manuilov, T. Asselah, A. Blank, F. Zoulim, M. Cornberg, S. Zeuzem

#### Long-term outcomes in BLV-treated patients

- 16 **Pregnancy outcomes following bulevirtide exposure during pregnancy: An analysis of clinical trial and postmarketing data**  
P. Jhand, A. Rodriguez Dominguez, D. Shing, F. Christian-Cox, S. Tseng, D. Manuilov, A. Lichtman
- 20 **Bulevirtide monotherapy prevents liver decompensation but not HCC in patients with HDV-related cirrhosis: 3-year results from an inverse probability-weighted European case-controlled study**  
E. Degasper, A. De Silvestri, D. Roulot, M.P. Anolli, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, J. Foucher, S. Metivier, M. Buti, A. Palom, G. D'Offizi, F. De Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridis, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmell, M.R. Brunetto, E. Rosselli del Turco, A. Ciancio, S. Lens, A. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, M.N. Hilleret, U. Merle, M. Cardoso, J. Branco, C. Gouveia, T.A. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, A. Loglio, A. Federico, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, L. Parlati, A. Gervais, A. Minello, I. Rosa, I. Costa Santos, F. Velasco, M. Puot, A. Horta, M. Machado, D. Fernandes, J. Oliveira, J. Vaz Alves, J. Flaherty, P. Lampertico
- 22 **Long-term clinical and virological outcomes of Bulevirtide monotherapy up to 4 years in CHD patients with cirrhosis: the SAVE-D study**  
E. Degasper, M.P. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, C. Schramm, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D'Offizi, F. De Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridis, G. Papatheodoridis, F. Van Bömmell, S. Lens, M.R. Brunetto, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciancio, A. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, S. Metivier, C. Coffin, S. Poulin, A. Mangia, M.N. Hilleret, U. Merle, M. Cardoso, A. Martins, C. Gouveia, K. Doucette, S. Borgia, A. Loglio, T.A. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, C. Fonseca, A.M. Vieira, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, L. Parlati, A. Gervais, A. Minello, M. Puoti, A. Horta, M. Machado, D. Fernandes, J. Oliveira, J. Vaz Alves, P. Lampertico
- 23 **Characterization of virological breakthroughs under Bulevirtide monotherapy: combined data from the SAVE-D and D-SHIELD cohorts**  
E. Degasper, M.P. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, C. Schramm, T. Reiberger, M.R. Brunetto, K. Agarwal, M. Buti, S. Zaltron, F. Tacke, H. Wedemeyer, M. Papatheodoridis, F. Van Bömmell, S. Lens, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Giráldez-Gallego, F. Calinas, M. Milella, L. Turco, A. Di Lorenzo, M. Tamé, P. Toniutto, A. Gasbarrini, L. Marinaro, F.P. Russo, A. Gori, I. Maida, T.A. Santantonio, R. Bruno, E.G. Giannini, I. Cacciola, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, S.L. Crocè, P. Lampertico on behalf of the SAVE-D and D-SHIELD investigators
- 28 **Mathematical modeling of 144-week bulevirtide monotherapy in HDV-infected patients with compensated cirrhosis and CSPH**  
A. Mhlanga, L. Shekhtman, E. Degasper, M.P. Anolli, S.C. Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, A. Callegaro, S.J. Cotler, H. Dahari, P. Lampertico
- 43 **Bulevirtide provides comparable virological control regardless of cirrhosis status: analysis of treatment response and breakthroughs from the D-Shield multicenter prospective study**  
M.P. Anolli, E. Degasper, G. D'Offizi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, M.R. Brunetto, B. Coco, A. Zaltron, O. Nozza, M. Milella, E. Rosselli Del Turco, L. Turco, A. Di Lorenzo, M. Tamé, P. Toniutto, A. Gasbarrini, L. Marinaro, F.P. Russo, C. Magni, I. Maida, A. Federico, T.A. Santantonio, R. Bruno, E.G. Giannini, I. Cacciola, G. Svegliati Baroni, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, S.L. Crocè, F. Pileri, R. Zampino, M. Persico, P. Pozzoni, A. Zoncada, A. Pellicelli, N. Coppola, M. Tonnini, E. Grassi, A. Soria, P. Caraceni, M. Dalla Bella, I. Arena, V. Esposito, P. Vitiello, M. Puoti, P. Lampertico
- 50 **Early gamma-glutamyl transferase decline mirrors virological response during bulevirtide therapy in chronic hepatitis D: a real-world longitudinal study**  
E.A. Gabor, L. Foroghi Biland, A. Alfieri, S. Ampollini, C. Boni, G. Missale

## POSTER EXHIBITION

- 56 **Clinical and economic value of early treatment with bulevirtide in chronic hepatitis delta virus**  
M. Buti, J.L. Calleja, M.A. Rodríguez, R. Domínguez-Hernández, N. Espinoza-Cámac, V. Martín-Escudero, H. Cantero
- 58 **Improvement of non-invasive fibrosis tests and clinically significant portal hypertension according to Baveno VII criteria during Bulevirtide monotherapy in patients with HDV-related cirrhosis: a longitudinal analysis of the SAVE-D study**  
E. Degasper, M.P. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D'Offizi, F. De Maria, C. Zöllner, F. Tacke, Q. Wu, H. Wedemeyer, M. Papatheodoridis, G. Papatheodoridis, F. Van Bömmell, S. Lens, M.R. Brunetto, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciano, A. Giraldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, S. Metivier, C. Coffin, S. Poulin, A. Mangia, M.N. Hilleret, U. Merle, M. Cardoso, A. Martins, C. Gouveia, K. Doucette, S. Borgia, A. Loglio, T.A. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, C. Fonseca, A.M. Vieira, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, L. Parlati, A. Gervais, A. Minello, M. Puoti, A. Horta, M. Machado, D. Fernandes, J. Oliveira, J. Vaz Alves, P. Lampertico
- 79 **Bulevirtide discontinuation after long-term HDV RNA suppression in patients with CHD: impact of different HDV RNA assays on patient selection and virological outcomes (Robogene 2.0 vs. AltoStar 1.5)**  
M.P. Anolli, S. Uceda Renteria, E. Degasper, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
- 82 **Integrated Pharmacogenetic, Pharmacokinetic, and Clinical Evaluation of Bulevirtide in Patients with Chronic Hepatitis D**  
J. Cusato, M. Antonucci, A. Palermi, A. Manca, A. De Nicolò, C. Quarta, A. D'Avolio, G. Di Perri, S. Bonora and L. Marinaro
- 94 **Viral kinetics modelling of initial and retreatment in HDV patients under bulevirtide monotherapy**  
D. Shemla, K. Deterding, L. Shekhtman, S.J. Cotler, A. Mhlanga, E. Degasper, P. Lampertico, D. Sambarino, L. Sandmann, K. Port, S. Aleman, A. Olsen, M. Jachs, T. Reiberger, M. Brunetto, G. Ricco, H. Dahari, H. Wedemeyer
- 97 **Real-world effectiveness and safety of Bulevirtide in patients with chronic hepatitis D: a single-center cohort from Romania**  
V. Molagic, I. Staicu, A. Mihalache, A. Saran, A. Cozma, D. Neagu, A. Marinescu, C. Gheorghe, C. Tiliscan, R. Nastase, D. Toma, A. Negru, A. Orfanu, S. Arama, V. Arama
- 102 **Correlation between HDV RNA and anti-HDV dynamics in chronic hepatitis D patients treated with Bulevirtide**  
G. Ricco, D. Cavallone, P. Colombatto, B. Coco, F. Oliveri, F. Damone, G. Petralli, V. Romagnoli, A. Salvati, L. Surace, A. Cali, B. Vianello, F. Bonino, M. R. Brunetto
- 110 **Bulevirtide treatment is associated with improvements in disease severity in patients with detectable hepatitis delta virus RNA: Results from a real-world study in Europe**  
P. Lampertico, F. Hennessy, T. Pennant, D. Graham, F. Barrable, A. Hinds, C. Burk, C. Kim, M. Rock, M. Buti
- 111 **Association of bulevirtide use with changes in ALT: Results from a real-world study in Europe**  
P. Lampertico, F. Hennessy, T. Pennant, D. Graham, F. Barrable, A. Hinds, C. Burk, C. Kim, M. Rock, M. Buti
- 73 **Real-world 72-week virological and biochemical responses to bulevirtide in Romanian patients with chronic hepatitis D: data from a multicentre registry**  
L. Gheorghe, M. Ghioca, M. Chitul, C. Radu, M. Manuc, C. Gheorghe, M. Diclescu, A. Trifan, L. Huiban, M. Radu, F. Căruntu, L. Sandulescu, D. Gheonea, C. Radu, B. Procopet, C. Pop, N. Tiuca, R. Sirli, S. Iacob
- 75 **Health-related quality of life during bulevirtide treatment in a Romanian cohort**  
L. Gheorghe, M. Ghioca, M. Chitul, C. Radu, M. Manuc, C. Gheorghe, M. Diclescu, A. Trifan, L. Huiban, M. Radu, F. Căruntu, L. Sandulescu, D. Gheonea, C. Radu, B. Procopet, C. Pop, N. Tiuca, R. Sirli, S. Iacob
- 3 **Hepatic recompensation according to Baveno VII in decompensated chronic hepatitis Delta treated with bulevirtide: a multicenter experience**  
M. Meszaros, G.P. Pageaux, M. Viganò, E. Farina, C. Bouzbib, S. Dharancy, T. Antonini, S. Fagioli, A. Loglio

## Anti-HBs and siRNA combination

- 9 **SOLSTICE Week 48 subgroup analysis: Impact of BMI on ALT normalization after successful viral control in participants with chronic hepatitis delta virus infection treated with elebsiran and tobevibart**  
A. Jucov, T. Asselah, A. Streinu-Cercel, E. Gane, H. Wedemeyer, P. Lampertico, P. Kennedy, M.A. Chattergoon, B.L. Bullard, C. Huang, R. Acosta, S. Chow, C. Hwang, C. Pilowa, T. Correll, K. Agarwal
- 24 **Efficacy and safety of elebsiran (VIR-2218) in combination with tobevibart (VIR-3434) or tobevibart alone in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phase 2 SOLSTICE trial**  
T. Asselah, A. Streinu-Cercel, A. Jucov, E. Gane, H. Wedemeyer, P. Lampertico, P. Kennedy, M.A. Chattergoon, B.L. Bullard, C. Huang, R. Acosta, C. Pilowa, T. Correll, K. Agarwal

## POSTER EXHIBITION

### Other therapeutic approaches for HDV

- 4 **Libevitug treatment in chronic hepatitis D: virologic, biochemical, and biomarker improvements through 48 weeks**  
S.S. Hamid, Y. Xie, Z. Abbas, C. Wu, X.Z. Wang, A. Majeed, L. Zhang, X.N. Wu, O. Afzal, S. Nazir, H. Zhou, J. Wu, F. Guo, Z.G. Wang, Q. Xu, X. Zhou, L.F. Zou, Y.H. Qi, G.Y. Li, P. Chen, J.Y. Wen, Z.M. Zhou, X.P. Chen, B. Ye, Y. Zhang, B. Chen, J.H. Shui, W.H. Li, J.D. Jia, J.Q. Niu
- 25 **Brelvitug Monotherapy for the Treatment of Chronic Hepatitis D: Primary 24 Week Efficacy and Safety Results from the AZURE-1 Phase 2b Study**  
T. Kushner, D. Yardeni, M. Dobryanska, A. Jucov, D. Dieterich, J. Feld, M. Butsashvili, E. Dolmazashvili, D. Gerov, T. Khuchua, T. Saadi, D. Kaplan, J. Park, D. Pavlov, M. Radicheva, C. Coffin, E. Gane, S. Poulin, I. Jacobson, M. Levy, M. Sulkowski, N. Terrault, K. Doucette, N. Reau, S. Strasser, T. Tanaka, A. Duzik, S. Tan, S. Naim, W. Garner, C. Pace, H. Javanbakht, N. Shulman, S. Hamid, C. Yurdaydin (P. D. Weerasinghe)
- 26 **Brelvitug Monotherapy for the Treatment of Chronic Hepatitis D: Primary 24-Week Efficacy and Safety Results in Patients with Baseline Platelet Counts <100,000/ $\mu$ L from the AZURE-1 Phase 2b Study**  
D. Dieterich, D. Yardeni, T. Kushner, M. Dobryanska, A. Jucov, J. Feld, M. Butsashvili, E. Dolmazashvili, D. Gerov, T. Khuchua, T. Saadi, D. Kaplan, J. Park, D. Pavlov, M. Radicheva, C. Coffin, E. Gane, S. Poulin, I. Jacobson, M. Levy, M. Sulkowski, N. Terrault, K. Doucette, N. Reau, S. Strasse, T. Tanaka, A. Duzik, S. Tan, S. Naim, W. Garner, D. Weerasinghe, M. Bosse, N. Shulman, C. Yurdaydin, S. Hamid
- 86 **Efficacy and Safety of Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta in Mongolia**  
G. Jargalsaikhan, B. Narantuya, B. Batkhuy, M. Batkhuy, B. Dashi, T. Ulziybadrakh, O. Lkhagva-Ochir, N. Dashdorj
- 95 **Predicting time to cure in HDV patients treated with bulevirtide and pegylated interferon-alpha in the SEE-D trial**  
A. Mhlanga, E. Zavalis, S.J. Cotler, K. Lindahl, L. Shekhtman, S. Cederberg, A. Olsson, N. Björkström, P. Lampertico, H. Wedemeyer, S. Aleman, H. Dahari
- 96 **Mathematical modeling reveals mechanisms of response to pegylated interferon-alpha in chronic hepatitis D: Insights from the D-LIVR Study**  
A. Omes, L. Shekhtman, A. Mhlanga, T. Heller, C. Koh, J. Glenn, T. Asselah, S. Hamid, D. Yardeni, S.J. Cotler, H. Dahari, O. Etzion
- 104 **Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial**  
R. Taylor, T. Asselah, O. Etzion, S. Hamid, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, T. Petrivna, L. Gheorghe, G. Stancu, N. Voronkova, N. Bursukova, S. Aleman, J. Feld, R. Gish, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn
- 105 **Post-treatment response following 48 weeks of lonafarnib therapy: analysis of 24-week follow-up in the phase 3 D-LIVR trial in chronic hepatitis delta**  
S. Hamid, O. Etzion, T. Asselah, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, T. Petrivna, L. Gheorghe, G. Stancu, N. Voronkova, N. Bursukova, S. Aleman, J. Feld, R. Taylor, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn
- 106 **Clinical significance of ALT dynamics following lonafarnib treatment cessation in the phase 3 D-LIVR trial**  
O. Etzion, S. Hamid, T. Asselah, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, H. Bonkovsky, J. Lewis, J. Ahmad, S. Aleman, J. Feld, R. Taylor, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn
- 107 **A 2log decrease in HDV RNA plus normal ALT 6 months post lonafarnib-based therapy for hepatitis delta virus (HDV) is sufficient for long-term clinical benefit**  
C. Yurdaydin, C. Koh, M.Ö. Gülnar, O. Metin, E. Yurdu, S. Özer, O. Keskin, M. Gümüşsoy, E. Bodakçi, X. Deda, Z.M. Ellik, S. Aghayeva, G. Gençdal, M. Akyildiz, M. Zeybel, R. Idilman, M.A. Bozdayi, I. Choong, N. Dashdorj, N. Dashdorj, E. Mills, O. Harari, T. Heller, J.S. Glenn
- 118 **The efficacy and safety of siRNA oxisiran in patients with chronic hepatitis D: Interim results through treatment Week 36 from the phase 2a RC04T001 trial**  
K. Lindahl, M. Hedenstierna, K. Johansson Århem, C. Gahrton, P. Ljungman, C. Millbourn, M. Tremoy, S. Ueckert, S. Svedlund, A. Gabrielsen, P. Lampertico, H. Wedemeyer, S. Aleman

## UNMET NEEDS IN HDV

### Global modeling of HDV antiviral therapy impact

- 6 **Clinical Impact of Multidisciplinary Care in an Oncology Patient With HIV and Chronic Viral Hepatitis Receiving Chemotherapy**  
A.M. Spera, C. D'Amore, V. Conti, A. Filippelli, M. Onofrio, P. Pagliano
- 34 **Beyond Fibrosis: Chronic Hepatitis D Is Associated with Worse Patient-Reported Outcomes and a Distinct Clinical Burden Compared with Hepatitis B**  
M. Buti, G. Papatheodoridis, T. Kushner, M. Papatheodoridis, K.M. AlNaamani, C. Villela-Nogueira, B. Munkhbat, S. Gidaagaya, M.L. Yu, C. W. Spearman, I. Jacobson, Y. Eguchi, M. El-Kassas, P. Lampertico, Y. Yilmaz, M. Stepanova, J. P. Ong, Z.M. Younossi

## POSTER EXHIBITION

### MASLD in HBV and HDV

- 41 **Cardiometabolic profile of european patients with chronic hepatitis delta: insights from the Save-D and D-Shield cohorts**  
 MP. Anolli, E. Degasper, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, M. Jachs, T. Reiberger, C. Schramm, MR. Brunetto, F. Van Bömmel, S. Zaltron, L. Turco, C. Zöllner, TA. Santantonio, I. Carey, A. Federico, M. Tamè, A. Di Lorenzo, M. Buti, F. Calinas, F. Morisco, M. Papatheodoridi, FP. Russo, A. Mangia, P. Toniutto, N. Coppola, Q. Wu, J. Dumortier, EG. Giannini, E. Rosselli Del Turco, S. Aleman, S. De Nicola, M. Maracci, L. Marinaro, M. Milella, A. Pellicelli, B. Pinchera39, M. Puoti40, D. Roulot41, LS Crocè42, I. Maida43, U. Merle44, M. Cardoso45, A. Zoncada46, P. Torre47, F. Pileri48, A. Romano49, M. Tonnini50, P. Vitiello, R. Zampino, P. Lampertico on behalf of the SAVE-D and D-SHIELD investigators

### Liver transplantation for HDV

- 5 **HDV infection in the liver transplantation setting: less rare than expected but associated with excellent outcomes**  
 S. Battistella, L. Turco, MC. Morelli, G. Frassanito, N. De Maria, L. Pasulo, S. Fagioli, C. Di Benedetto, MF. Donato, B. Magro, D. Pagano, S. Bhoori, V. Mazzaferro, A. Lauterio, L. De Carlis, D. Forastiere, M. Rendina, D. Angrisani, A. Galeota Lanza, G. Scandali, G. Svegliati Baroni, S. Piano, P. Angeli, C. Manuli, S. Martini, P. De Simone, PG. Vacca, D. Ghinolfi, R. Lionetti, V. Giannelli, L. Mameli, E. Fornasiere, P. Toniutto, M. Biolato, FR. Ponziani, I. Lenci, A. Ferrarese, N. Passigato, S. Marengo, E. Giannini, F. Ferri, S. Trapani, P. Grossi, A. Aghemo, A. Zanetto, FP. Russo, P. Burra
- 33 **Hepatitis D and liver transplantation over two decades: Younger recipients, more decompensated disease, but superior post-transplant survival. A study from the ELTR (European Liver Transplant Registry)**  
 G. Germani, M. Buti, G. Papatheodoridi, P. Lampertico, R. Adam, V. Karam, S. Alqahtani, M. Papatheodoridi, M. Stepanova, P. Burra, Z. Younossi
- 72 **Excellent long-term survival and low viral recurrence after liver transplantation for HBV/HDV coinfection**  
 S. Iacob, M. Chitul, R. Cerban, C. Este, M. Ghioca, R. Iacob, C. Gheorghe, M. Grasu, I. Lupescu, D. Hrehoret, V. Brasoveanu, I. Popescu, L. Gheorghe

### AI-based approaches for liver diseases: lessons learned

- 19 **Synthetic data generation by artificial intelligence predicts clinical outcomes in untreated and Bulevirtide-treated patients with chronic hepatitis delta**  
 S. D'Amico, E. Degasper, S. de Nicola, N. Pugliese, MP. Anolli, M. Borghi, S. Baccino, I. Ferrari, D. Roulot, M. Della Porta, A. Aghemo, P. Lampertico
- 27 **Artificial intelligence and synthetic data to investigate predictors of clinical outcomes in Bulevirtide-treated patients with chronic hepatitis delta**  
 E. Degasper, S. Baccino, S. D'Amico, S. de Nicola, N. Pugliese, MP. Anolli, M. Borghi, I. Ferrari, M. Della Porta, A. Aghemo, P. Lampertico